Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term Non-UCP2 mRNAs with seed-region complementarity refers to a heterogeneous population of messenger RNA (mRNA) transcripts that possess sequence motifs complementary to the seed regions (nucleotides 2-8) of microRNAs (miRNAs) that typically regulate Uncoupling Protein 2 (UCP2). These transcripts are not a single therapeutic target but rather a collective group of potential off-targets or competing endogenous RNAs (ceRNAs) that can sequester miRNAs such as miR-133, miR-15a, or miR-214. By binding these shared miRNAs, these mRNAs can indirectly modulate the expression of UCP2 and other genes within the same regulatory network, a phenomenon known as the ceRNA effect. In the development of RNA-based therapeutics, such as miRNA mimics or antagomirs, this group of molecules represents a significant challenge for drug specificity and safety. If a drug is designed to alter UCP2 levels by targeting its regulatory miRNAs, these complementary non-target mRNAs may be inadvertently silenced or upregulated, potentially leading to unintended biological consequences in metabolic or oncological pathways. Consequently, they are primarily analyzed during preclinical safety assessments to predict and mitigate systemic off-target effects (Bartel, 2009; Salmena et al., 2011; Poy et al., 2004).
Competitive binding to the seed region of microRNAs (miRNA sponging), leading to the titration of miRNA activity away from the primary target (UCP2).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-UCP2 mRNAs with seed-region complementarity.